Charter Life Sciences




	Columbia Grants Health Fidelity Exclusive License to MedLEE NLP January 11, 2012 EnteroMedics Announces Completion of Patient Enrollment and Device Implantation in the ReCharge Pivotal Trial for Obesity December 28, 2011 EnteroMedics Receives First Approval for the Active Implantable Medical Device Components of the Maestro System From Australian Therapeutic Goods Administration (TGA) December 13, 2011 Inviragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax December 7, 2011 EnteroMedics Announces Updated Data From VBLOC DM2 ENABLE Study and Caloric Intake Study Results to Be Presented at the 29th Annual Obesity Society Meeting October 3, 2011 EnteroMedics Announces Presentation of Maestro(R) RC System Clinical Data at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders September 2, 2011 Inviragen and University of Texas Medical Branch Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine August 15, 2011 San Diego's KFx Medical Corporation Files Patent Infringement Suit Against Arthrex August 2, 2011 International Vaccine Institute and Inviragen Announce a Collaboration to Accelerate Development of a Dengue Vaccine August 2, 2011 Minimally Invasive Devices, Inc. Awarded CE Mark for FloShield July 20, 2011 Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore June 15, 2011 EnteroMedics Announces Maestro® RC System Updated Weight Loss Data to Be Presented at the American Society for Metabolic and Bariatric Surgery Annual Meeting June 14, 2011 EnteroMedics Announces First Implant in ReCharge Pivotal Trial for Obesity May 18, 2011 Xlumena, Inc. Closes $7M Series B Venture Financing Round April 28, 2011 EnteroMedics Receives CE Mark Certification for the Maestro RC System, Allowing Australian Regulatory Application to Move Forward March 28, 2011 Inviragen and Duke-NUS Form Collaborative Vaccine Research and Development Program January 26, 2011 EnteroMedics Announces Data From Australian Patient Cohort in EMPOWER Study and From Caloric Intake Study November 8, 2010 Novel Recombinant Chikungunya Virus Vaccine Shown to be Safe and Effective in Multiple Animal Models November 4, 2010 Inviragen Receives Two Therapeutic Discovery Project Grants for Vaccine Development November 2, 2010 Inviragen Initiates DENVax Phase 1 Clinical Testing in Colombia October 25, 2010 EnteroMedics Announces Updated Data from VBLOC-DM2, EMPOWER and VBLOC RF2 Studies October 20, 2010 Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine October 12, 2010 EnteroMedics Completes $6.3 Million Convertible Preferred Stock Offering September 30, 2010 EnteroMedics Achieves Major Milestones in Global Regulatory and Commercialization Strategy for the Maestro System August 2, 2010 KFx Medical Corporation Announced Today It Has Received FDA 510k Clearance for Product(s) Used in a Wide Variety of Arthroscopic Tenodesis Knee Procedures Such as: ACL, PCL, and Patellofemoral Ligament (MPFL) Reconstruction May 25, 2010 Inviragen’s Dengue Vaccine to Begin Clinical Testing May 19, 2010 Inviragen Merger Profiled in Inc. Magazine May 7, 2010 FDA Clears Xlumena’s NAVIX™ Access Device April 28, 2010 EnteroMedics Extends Neuroblocking Technology Research and Development Collaboration March 17, 2010 EnteroMedics Announces Regulatory Path Forward Following FDA Meeting March 15, 2010 EnteroMedics Announces Regulatory Path Forward Following FDA Meeting January 28, 2010 EnteroMedics Announces Weight Loss, Hypertension and Diabetes Data from EMPOWER and ENABLE Studies Januray 14, 2010 EnteroMedics Announces Preliminary Results from Detailed Review of EMPOWER Study November 12, 2009 Inviragen Merges with SingVax and Completes $15 million Series A Financing October 6, 2009 KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery September 9, 2009 Visioneering Technologies Raises $2.5M Series B April 28, 2009 Visioneering Technologies Inc Raises $5 Million in Funding For New Presbyopia Solution April 14, 2009 EnteroMedics Announces $15.89 Million Private Placement February 20, 2009 EnteroMedics Announces Eighteen-Month Excess Weight Loss Results from its VBLOC-RF2 Feasibility Study January 12, 2009 EnteroMedics Announces $20 Million Debt Financing November 21, 2008 APT Pharmaceuticals Secures $32 Million in Series B Financing September 30, 2008 EnteroMedics' Data from VBLOC-RF2 Feasibility Study and VBLOC-RC Study Presented Today at the American Society for Metabolic and Bariatric Surgery Meeting June19, 2008 XLumena Spots $6M For Ultrasound Devices June 4, 2008 Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids APRIL 28, 2008 Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors APRIL 25, 2008 EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients February 26, 2008 KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing February 20, 2008 EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy January 8, 2008 EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity January 7, 2008 CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy January 7, 2008 APT Pharmaceuticals Expands Management Team NOVEMBER 19, 2007 EnteroMedics Announces Initial Public Offering NOVEMBER 14, 2007 APT Pharmaceuticals Closes New $22 Million Funding Round OCTOBER 4, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial SEPTEMBER 20, 2007 Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids AUGUST 21, 2007 KFx Medical Corporation Closes $10 Million Series B Financing AUGUST 9, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial JUNE 18, 2007 CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President JUNE 6, 2007 APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection JUNE 5, 2007 Enteromedics Files Registration Statement for Proposed Initial Public Offering MAY 25, 2007 CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy APRIL 10, 2007 Athenagen Announces Name Change to CoMentis FEBRUARY 10, 2007 Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study JANUARY 31, 2007 Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease DECEMBER 13, 2006 Mirabilis Medica Names Mike Connolly CEO OCTOBER 3, 2006 Athenagen Raises $50 Million in Series B Financing SEPTEMBER 28, 2006 Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents SEPTEMBER 26, 2006 Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids AUGUST 29, 2006 Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD AUGUST 21, 2006 Athenagen Completes Merger with Zapaq AUGUST 14, 2006 KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation AUGUST 10, 2006 Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia JUNE 15, 2006 Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline APRIL 13, 2006 Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma MARCH 23, 2006 Athenagen Adds A. Barr Dolan to its Board of Directors FEBRUARY 22, 2006 Previous News Stories >


	About CLS
	CHARTER LIFE SCIENCES (“CLS”) is a clinical stage life sciences venture capital investor. CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial clinical proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public. Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. We take a team approach to all of our investments, and our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies. We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to investing in early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your preclinical biotech or medical device company will not be compared against a PIPE investment in an undervalued Phase III company. Early stage is what we do, and all we do. We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one. Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.